Lutathera
Payments companies reported to CMS as associated with Lutathera. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lutathera, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lutathera
These are the largest totals companies reported as associated with Lutathera. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sandy Kotiah | Baltimore, MD | Medical Oncology | $12,617.01 |
| Alton Sartor | Rochester, MN | Medical Oncology | $9,467.84 |
| Neal Shore | Myrtle Beach, SC | Urology | $5,600.00 |
| Lesley Flynt | Houston, TX | Nuclear Medicine | $5,478.30 |
| Mark Fleming | Hampton, VA | Hematology & Oncology | $4,725.00 |
| Aman Chauhan | San Francisco, CA | Medical Oncology | $4,504.50 |
| Matthias Holdhoff | Baltimore, MD | Medical Oncology | $4,387.50 |
| Jana Ivanidze | New York, NY | Diagnostic Radiology | $4,062.50 |
| Daniel Halperin | Houston, TX | Medical Oncology | $3,712.50 |
| Robert Ramirez | Nashville, TN | Medical Oncology | $3,625.64 |
Prescribed Lutathera?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.